Metagenomic next-generation sequencing for rapid detection of pulmonary infection in patients with acquired immunodeficiency syndrome.
Acquired immunodeficiency syndrome
Diagnosis
Metagenomic next-generation sequencing
Pulmonary infection
Journal
Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152
Informations de publication
Date de publication:
10 Jul 2023
10 Jul 2023
Historique:
received:
22
03
2023
accepted:
05
07
2023
medline:
12
7
2023
pubmed:
11
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Acquired immunodeficiency syndrome (AIDS) is associated with a high rate of pulmonary infections (bacteria, fungi, and viruses). To overcome the low sensitivity and long turnaround time of traditional laboratory-based diagnostic strategies, we adopted metagenomic next-generation sequencing (mNGS) technology to identify and classify pathogens. This study enrolled 75 patients with AIDS and suspected pulmonary infections who were admitted to Nanning Fourth People's Hospital. Specimens were collected for traditional microbiological testing and mNGS-based diagnosis. The diagnostic yields of the two methods were compared to evaluate the diagnostic value (detection rate and turn around time) of mNGS for infections with unknown causative agent. Accordingly, 22 cases (29.3%) had a positive culture and 70 (93.3%) had positive valve mNGS results (P value < 0.0001, Chi-square test). Meanwhile, 15 patients with AIDS showed concordant results between the culture and mNGS, whereas only one 1 patient showed concordant results between Giemsa-stained smear screening and mNGS. In addition, mNGS identified multiple microbial infections (at least three pathogens) in almost 60.0% of patients with AIDS. More importantly, mNGS was able to detect a large variety of pathogens from patient tissue displaying potential infection and colonization, while culture results remained negative. There were 18 members of pathogens which were consistently detected in patients with and without AIDS. In conclusion, mNGS analysis provides fast and precise pathogen detection and identification, contributing substantially to the accurate diagnosis, real-time monitoring, and treatment appropriateness of pulmonary infection in patients with AIDS.
Sections du résumé
BACKGROUND
BACKGROUND
Acquired immunodeficiency syndrome (AIDS) is associated with a high rate of pulmonary infections (bacteria, fungi, and viruses). To overcome the low sensitivity and long turnaround time of traditional laboratory-based diagnostic strategies, we adopted metagenomic next-generation sequencing (mNGS) technology to identify and classify pathogens.
RESULTS
RESULTS
This study enrolled 75 patients with AIDS and suspected pulmonary infections who were admitted to Nanning Fourth People's Hospital. Specimens were collected for traditional microbiological testing and mNGS-based diagnosis. The diagnostic yields of the two methods were compared to evaluate the diagnostic value (detection rate and turn around time) of mNGS for infections with unknown causative agent. Accordingly, 22 cases (29.3%) had a positive culture and 70 (93.3%) had positive valve mNGS results (P value < 0.0001, Chi-square test). Meanwhile, 15 patients with AIDS showed concordant results between the culture and mNGS, whereas only one 1 patient showed concordant results between Giemsa-stained smear screening and mNGS. In addition, mNGS identified multiple microbial infections (at least three pathogens) in almost 60.0% of patients with AIDS. More importantly, mNGS was able to detect a large variety of pathogens from patient tissue displaying potential infection and colonization, while culture results remained negative. There were 18 members of pathogens which were consistently detected in patients with and without AIDS.
CONCLUSIONS
CONCLUSIONS
In conclusion, mNGS analysis provides fast and precise pathogen detection and identification, contributing substantially to the accurate diagnosis, real-time monitoring, and treatment appropriateness of pulmonary infection in patients with AIDS.
Identifiants
pubmed: 37430367
doi: 10.1186/s12941-023-00608-9
pii: 10.1186/s12941-023-00608-9
pmc: PMC10334547
doi:
Substances chimiques
Azure Stains
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57Subventions
Organisme : the Science and Technology Planning Project of Nanning City
ID : 20203052
Organisme : the Youth Science and Technology Talents Cultivation Project of Nanning
ID : RC20180103
Informations de copyright
© 2023. The Author(s).
Références
Trends Biotechnol. 2019 Jan;37(1):72-85
pubmed: 30115375
Curr Opin HIV AIDS. 2014 Jan;9(1):63-71
pubmed: 24275674
Appl Environ Microbiol. 2008 Aug;74(16):5224-7
pubmed: 18567689
Med Mycol. 2017 Apr 1;55(3):285-294
pubmed: 27630251
Microorganisms. 2021 Sep 16;9(9):
pubmed: 34576860
Chest. 2017 Aug;152(2):295-303
pubmed: 28302496
Front Med (Lausanne). 2021 Oct 28;8:736064
pubmed: 34778300
BMC Pulm Med. 2022 Mar 29;22(1):112
pubmed: 35351079
Front Med (Lausanne). 2021 Mar 29;8:653294
pubmed: 33855038
Ann Periodontol. 1996 Nov;1(1):879-925
pubmed: 9118283
Int J STD AIDS. 1992 May-Jun;3(3):157-60
pubmed: 1616960
Infect Drug Resist. 2020 Feb 19;13:567-576
pubmed: 32110067
Front Microbiol. 2022 Feb 23;12:814944
pubmed: 35281304
BMC Pulm Med. 2019 Dec 19;19(1):252
pubmed: 31856779
Monaldi Arch Chest Dis. 1994 Dec;49(5):380-8
pubmed: 7841972
Front Cell Infect Microbiol. 2021 Mar 11;11:541092
pubmed: 33777827
Arch Pathol Lab Med. 1994 Jul;118(7):744-8
pubmed: 7517660
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
Emerg Microbes Infect. 2016 Feb 03;5:e10
pubmed: 26839146
Int J Mol Sci. 2022 Jan 14;23(2):
pubmed: 35055069
Curr Opin HIV AIDS. 2017 Mar;12(2):123-128
pubmed: 28059957
Ann Intern Med. 1996 Apr 1;124(7):633-42
pubmed: 8607591
Diagn Microbiol Infect Dis. 2010 Nov;68(3):330-3
pubmed: 20955918
East Afr Med J. 2000 Jan;77(1):13-5
pubmed: 10944831
Front Cell Infect Microbiol. 2018 Jun 25;8:205
pubmed: 29988504
BMC Pulm Med. 2020 Oct 15;20(1):268
pubmed: 33059646
J Infect. 2021 Apr;82(4):22-27
pubmed: 33609588
J Gen Virol. 2003 Jul;84(Pt 7):1649-1661
pubmed: 12810858
World J Gastroenterol. 2015 Oct 28;21(40):11450-7
pubmed: 26523109
Indian J Med Microbiol. 2019 Apr-Jun;37(2):133-140
pubmed: 31745012
Bioinformatics. 2015 Dec 15;31(24):4003-5
pubmed: 26323715
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
Int J Clin Exp Pathol. 2020 Jul 01;13(7):1727-1732
pubmed: 32782696
Scand J Infect Dis. 1996;28(5):463-7
pubmed: 8953675
J Biomol Tech. 2017 Apr;28(1):40-45
pubmed: 28337072
Clin Chest Med. 2013 Jun;34(2):205-16
pubmed: 23702171
PLoS Comput Biol. 2019 Nov 22;15(11):e1006863
pubmed: 31756192
Arch Pathol Lab Med. 1994 Sep;118(9):884-90
pubmed: 8080357
J Infect Public Health. 2021 Dec;14(12):1881-1886
pubmed: 34810142
Front Public Health. 2021 Aug 13;9:663093
pubmed: 34485213
J Clin Microbiol. 2001 Nov;39(11):3842-50
pubmed: 11682496
Patholog Res Int. 2011 Feb 10;2011:764293
pubmed: 21331327
Am J Ophthalmol. 2002 Aug;134(2):275-7
pubmed: 12140042
Diabetes Care. 2006 May;29(5):1058-64
pubmed: 16644637
Eur J Clin Microbiol Infect Dis. 2004 Nov;23(11):851-4
pubmed: 15558344
Clin Infect Dis. 2010 Dec 15;51(12):1458-62
pubmed: 21054180
Annu Rev Microbiol. 2015;69:425-44
pubmed: 26488280
J Acquir Immune Defic Syndr (1988). 1992;5(2):132-6
pubmed: 1732504
Eur Respir J. 2014 Jun;43(6):1698-708
pubmed: 24525448
J Assoc Physicians India. 2002 Sep;50:1110-4
pubmed: 12516691